Here are five highlights:
1. Mr. Hannon will replace current CEO Peter Crosby, who is retiring. Mr. Crosby will serve as a consultant to the company until the end of 2020.
2. Mr. Hannon will also serve as a director, effective Oct. 9.
3. With a 12-year career at NuVasive, Mr. Hannon served as the company’s president and COO.
4. Mainstay Medical develops ReActiv8, an implantable restorative neurostimulation system.
5. The company is conducting the ReActiv8 clinical trial to gather data for its FDA pre-market approval application.
More articles on devices:
Medtronic to study Infuse in PLF, TLIF spine surgeries in new pilot trials: 5 things to know
Medtronic, NuVasive, InVivo Therapeutics & more: 6 device company notes
Stryker completes Novadaq Technologies acquisition: 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
